Previously reported cardiac events in patients treated with alemtuzumab
Study . | Disease (n) . | No. of patients with cardiac events . | Cardiac event(s) . | Cumulative dose, mg . |
|---|---|---|---|---|
| Keating et al, 20027 | T-cell prolymphocytic leukemia (75) | 1 | Atrial fibrillation | Unspecified (acute reaction) |
| Damaj et al, 200211 | PTCL-nodal (1) | 1 | MI | 10 |
| Lundin et al, 19982 | B-cell lymphoma or MF (50) | 1 | MI | About 300* |
Study . | Disease (n) . | No. of patients with cardiac events . | Cardiac event(s) . | Cumulative dose, mg . |
|---|---|---|---|---|
| Keating et al, 20027 | T-cell prolymphocytic leukemia (75) | 1 | Atrial fibrillation | Unspecified (acute reaction) |
| Damaj et al, 200211 | PTCL-nodal (1) | 1 | MI | 10 |
| Lundin et al, 19982 | B-cell lymphoma or MF (50) | 1 | MI | About 300* |
PTCL indicates peripheral T-cell lymphoma; MI, myocardial infarction; and MF, mycosis fungoides.
Patient received 10 doses of 30 mg after an initial dose of either 3 mg or 10 mg (not specified).